Arradiance Partners to Expand to International Markets
Atomic Layer Deposition (ALD) technology with applications in night
vision, high energy physics, homeland security and biomedicine is
generating global interest. A 2011 Larta NSF-CAP1
participant, Arradiance recently signed partnerships
with Euris Semiconductor Services of France to support its GEMStar line
bench top ALD systems in Europe and HTL Co.
Japan Ltd. of Tokyo has agreed to a corresponding role in Asian markets.
Arradiance has also gained
licensing traction with their technology and recently sold their first
8” diameter capable GEMStar ALD systems, fulfilling a need for
affordable, large area photo detectors. Ken Stenton, CEO and Founder,
says “Working with Larta has enabled Arradiance to more clearly focus
our technology to the marketplace. The commercialization assistance has
proven invaluable for our corporate strategic planning.”
Angiotech Pharmaceuticals Acquires Bio-SEAL from Biopsy Sciences
, a 2006-2007 NIH-CAP Alum, develops new and innovative products for the medical market. Through Larta’s program, Angiotech Pharmaceuticals, a global specialty pharmaceutical and medical device company, connected with Biopsy Sciences and acquired Biopsy’s leading product, Bio-SEAL. Fisher said the acquisition couldn’t have been possible without their CAP mentor: “Our Larta advisor was a great resource and his advice was instrumental in our lead product Bio-SEAL being successfully acquired while we were in the CAP program.”
Inverness Medical Solutions transforms Zycare, Inc. to Alere
Zycare, Inc., NIH-CAP 2005-2006 graduate, was acquired by Inverness Medical Innovations. Zycare, which was renamed Alere after the acquisition, actively connects diagnostics and health management solutions. CEO Steve Holdaway said, “The presentation and preparation done with CAP were instrumental in helping us to fine tune our ‘story’ and thus in attracting other firms and investor groups.”
View More Success Stories!
commercialization assistance program has been immensely valuable to us. The
documents we developed as part of our
commercialization strategy report, most importantly our Commercialization
Road Map and Barriers to Market Entry, have already been put to good use in
our efforts to secure commercialization financing. As a young business, when
we think about our key success factors, the Larta CATP and our mentor are at
the top of the list."
Edie Johnston, Founder,
"The Larta Institute Global Bridge™ program was an excellent experience. We were able to discuss with investors and business advisers who provided us with knowledge of the business. Some of the points that we discussed were very important for my new international venture FKx Inc."
(Larta) seminar had a profound impact on the fundraising strategy and
methodology of our company. As a result, we were able to close a $1.2M series
A investment round. Positive momentum seems to build on itself, and several
more angels, and industry sources have expressed interest in our company."
Daniel Billing, CEO,
Innovent Medical Solutions
"Our Larta advisor has been flexible, well informed and highly creative
in his approach to adapting his experience to our particular project and
company capabilities- I never feel like we are getting a cookie-cutter
or canned series of responses during interactions."
Steve Lynch, Director of Learning Solutions,
"The NIH-CAP program was instrumental in the success of our company. Our advisor was a great resource and his advice was instrumental in our lead product Bio-SEAL being successfully acquired while we were in the CAP program. Larta and their entire team did a fantastic job organizing and running the program and I am still involved years after giving lectures and as a panelist."
John Fisher, CEO,
has been a beneficial platform for our strategic plan to be a renowned
vertically integrated Agbiotech firm. To Orchid Life, Larta Institute is
not just a trainer or mentor but is an important, long term, partner within
our ongoing vision, mission and goals."
Abdul Razak Mohd Isa,
"Our Principal Advisor’s feedback was really helpful. Our PA brought to us with a combination of detailed expertise and practical business approach. The Larta program forced us to hone our message and develop presentations we have relied on since we graduated. The program was worth while and we are glad that we were able to participate."
R.J. Sims Preston, CEO,
"This program has been very helpful for me. A company has licensed our technology and invested in conducting clinical trials and a new testing facility for EMAN. If Larta was not there, this definitely would not have been achievable."
Amin Malik Shah Abdul Majid ,
EMAN Testing and Research Laboratory
"The Larta consultants were essential in our success at securing phase II NSF funding on our commercialization plan. Since my colleagues and I had never gone through this process before, we learned a great deal for the next time we may submit a phase II proposal to NSF or any other government agency."
Cary Supalo, CEO,
Biosciences benefited greatly through its work with Larta. Our principal
advisor provided highly valuable feedback on our corporate strategy,
presentation and fundraising
program. While still working with Larta, Wave 80 consummated a $1
million angel financing round. Since completing the program, we
continue to work closely with our advisor and look forward to the next phase
of work with Larta."
Daniel Laser, CEO,
Wave 80 Biosciences
the Larta sessions, we got the chance to review the challenges facing us as
well as opportunities for our growth… Larta mentors have helped us focus and
define methods to meet our goals."
Nimrod Lev, CEO,
"The NIH-CAP provided us with high-caliber consulting work. Our Principal Advisor helped refine our roadshow presentation during our participating in the CAP program. With Larta’s assistance we were able to clearly communicate our vision and commercialization strategy to potential investors. Most significantly, the NIH-CAP has allowed us to commercialize on a global scale."
Mitchell Sanders, CEO,
matter where you are in the commercialization process – there is more to
learn from the experts assembled that support the CAP program. This time
around we will use the commercialization resources and expertise to assess
the viability of another product for the product pipeline."
Richard West, President & CEO,
Advanced Liquid Logic
"Larta has assembled one of the best commercialization assistance advisor teams in the world and has made substantial contributions to assisting small technology firms in bringing their advanced technologies from the laboratory to commercialization."
United Environment & Energy
"We would like to thank Larta Institute for guiding us to commercialize our veterinary diagnostic test kits. The “Commercialization Assistance Program” has been a great success and we managed to make some key contacts that may help the company to grow internationally."
Do Yew Tan,
Asia-Pacific Special Nutrients
Larta PA was instrumental in providing timely, actionable, and deeply
insightful guidance that has helped our company to navigate through the
wilderness that is startup life. The PA program has been one of the best
components, and privileges , of the NSF SBIR program. For the purposes
of this startup, I have found the Larta mentorship as valuable as my time on
Wall Street as an M&A investment banker, as a consultant at McKinsey
& Co, and as a student at Wharton earning my MBA."
David Kim, CEO,
"We were consistently pleased with the quality of instruction and consultation from Larta. We were also pleased to participate in the past forums presented by Larta. Because of the excellent guidance of the principal advisors and the Larta personnel, we have been able to successfully present VRMC to investors."
Mark Wiederhold, CEO,
Virtual Reality Medical Center
"We've benefited immensely through Larta's mentoring as well as participating in the Ag Innovation Showcase 2011 where we had the opportunity to meet key opinion leaders of the AgBio ecosystem. As a direct result of this, we are now discussing a key strategic project with Life Technologies, a US company that’s a world leader in gene sequencing technologies."
Huan Ung, CEO,
GS Biotech S/B
was integral in aiding in the development of our NSF commercialization plan.
Often times I wonder if Advantageous Systems would have been as successful as
we are now if it weren't for the help of Larta and our principal advisor."
Adam Stein, CEO,